Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2922 (LINC02922) is a long intergenic non-coding RNA (lincRNA), a member of a class of RNA molecules transcribed from intergenic regions that do not encode proteins[1][3]. LincRNAs like LINC02922 are typically transcribed by RNA polymerase II, can have multiple exons and a polyadenylated tail, and are involved in diverse regulatory processes in the cell, such as chromatin remodeling, epigenetic modification, regulation of neighboring or distant gene expression, and acting as scaffolds for protein complexes[3]. While specific biological or disease associations for LINC02922 are not currently reported in the provided sources, lincRNAs in general can act as regulators of oncogenes or tumor suppressors, and some are implicated in cancer or other diseases[3][5]. There is currently no evidence that LINC02922 is a direct therapeutic target, biomarker, or interacts with any drugs[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2922 (LINC02922).